However, as we previously demonstrated in a first cohort of 80 patients (10), we confirmed in this new independent cohort of metastatic CRC patients, that overexpression of HLA-E/β2m by tumor cells in primary tumors was significantly associated with a worse OS (median OS 35.97 months for HLA-E+ primary tumors vs 57.87 months for HLA-E− primary tumors; log rank test = 0.0012) (Figure 5A). This evidence concerns the gene HLA-E and neoplasm.